[go: up one dir, main page]

FR3059550B1 - Traitement des troubles causes par l'alcoolisation foetale (tcaf) - Google Patents

Traitement des troubles causes par l'alcoolisation foetale (tcaf) Download PDF

Info

Publication number
FR3059550B1
FR3059550B1 FR1661813A FR1661813A FR3059550B1 FR 3059550 B1 FR3059550 B1 FR 3059550B1 FR 1661813 A FR1661813 A FR 1661813A FR 1661813 A FR1661813 A FR 1661813A FR 3059550 B1 FR3059550 B1 FR 3059550B1
Authority
FR
France
Prior art keywords
fetal
treatment
tcaf
alcoholization
disorders caused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1661813A
Other languages
English (en)
Other versions
FR3059550A1 (fr
Inventor
Bruno Jose Gonzalez
Stephane Marret
Matthieu Jean Alexandre Lecuyer
Annie Laquerriere
Soumeya Bekri
Celine Lesueur
Sylvie Marguerite Alberte Jegou
Pascale Yvonne Josephine Marcorelles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Rouen
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Rouen
Original Assignee
Universite de Rouen
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Rouen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1661813A priority Critical patent/FR3059550B1/fr
Application filed by Universite de Rouen, Institut National de la Sante et de la Recherche Medicale INSERM, Centre Hospitalier Universitaire de Rouen filed Critical Universite de Rouen
Priority to EP17821808.7A priority patent/EP3548060A1/fr
Priority to PCT/EP2017/081159 priority patent/WO2018100143A1/fr
Priority to CN201780084741.4A priority patent/CN110225761A/zh
Priority to JP2019529500A priority patent/JP2020503275A/ja
Priority to CA3045080A priority patent/CA3045080A1/fr
Priority to AU2017367175A priority patent/AU2017367175A1/en
Priority to BR112019011141A priority patent/BR112019011141A2/pt
Priority to US16/465,465 priority patent/US20190351018A1/en
Priority to KR1020197018530A priority patent/KR20190109398A/ko
Publication of FR3059550A1 publication Critical patent/FR3059550A1/fr
Application granted granted Critical
Publication of FR3059550B1 publication Critical patent/FR3059550B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Food Science & Technology (AREA)

Abstract

La présente invention concerne un facteur de croissance placentaire (PIGF) en tant que médicament pour son utilisation dans la prévention et/ou le traitement des troubles causés par l'alcoolisation foetale (TCAF) choisis dans le groupe comprenant le syndrome d'alcoolisation foetale (SAF), l'atteinte vasculaire cérébrale et l'hypotrophie d'un sujet ayant été exposé à l'alcool in utero. La présente invention concerne également une composition pharmaceutique ou un produit comprenant le PIGF pour ces mêmes applications thérapeutiques.
FR1661813A 2016-12-01 2016-12-01 Traitement des troubles causes par l'alcoolisation foetale (tcaf) Expired - Fee Related FR3059550B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR1661813A FR3059550B1 (fr) 2016-12-01 2016-12-01 Traitement des troubles causes par l'alcoolisation foetale (tcaf)
US16/465,465 US20190351018A1 (en) 2016-12-01 2017-12-01 Placental growth factor for the treatment of fetal alcohol syndrome disorders (fasd)
CN201780084741.4A CN110225761A (zh) 2016-12-01 2017-12-01 用于治疗胎儿酒精综合征障碍(fasd)的胎盘生长因子
JP2019529500A JP2020503275A (ja) 2016-12-01 2017-12-01 胎児性アルコール症候群障害（ｆａｓｄ）の治療のための胎盤増殖因子
CA3045080A CA3045080A1 (fr) 2016-12-01 2017-12-01 Facteur de croissance placentaire pour le traitement des troubles causes par l'alcoolisation foetale (tcaf)
AU2017367175A AU2017367175A1 (en) 2016-12-01 2017-12-01 Placental growth factor for the treatment of fetal alcohol syndrome disorders (FASD)
EP17821808.7A EP3548060A1 (fr) 2016-12-01 2017-12-01 Facteur de croissance placentaire pour le traitement des troubles causes par l'alcoolisation foetale (tcaf)
PCT/EP2017/081159 WO2018100143A1 (fr) 2016-12-01 2017-12-01 Facteur de croissance placentaire pour le traitement des troubles causes par l'alcoolisation foetale (tcaf)
KR1020197018530A KR20190109398A (ko) 2016-12-01 2017-12-01 태아알콜증후군 장애(fasd)의 치료를 위한 태반 성장인자
BR112019011141A BR112019011141A2 (pt) 2016-12-01 2017-12-01 fator de crescimento placentário, plgf para uso, composição farmacêutica e pigf ou composição para uso

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1661813A FR3059550B1 (fr) 2016-12-01 2016-12-01 Traitement des troubles causes par l'alcoolisation foetale (tcaf)
FR1661813 2016-12-01

Publications (2)

Publication Number Publication Date
FR3059550A1 FR3059550A1 (fr) 2018-06-08
FR3059550B1 true FR3059550B1 (fr) 2020-01-03

Family

ID=58609478

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1661813A Expired - Fee Related FR3059550B1 (fr) 2016-12-01 2016-12-01 Traitement des troubles causes par l'alcoolisation foetale (tcaf)

Country Status (10)

Country Link
US (1) US20190351018A1 (fr)
EP (1) EP3548060A1 (fr)
JP (1) JP2020503275A (fr)
KR (1) KR20190109398A (fr)
CN (1) CN110225761A (fr)
AU (1) AU2017367175A1 (fr)
BR (1) BR112019011141A2 (fr)
CA (1) CA3045080A1 (fr)
FR (1) FR3059550B1 (fr)
WO (1) WO2018100143A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3081707A1 (fr) * 2018-05-30 2019-12-06 Universite De Rouen Normandie Traitement des troubles neurologiques causes par l'alcoolisation foetale
US11883186B2 (en) * 2019-03-06 2024-01-30 San Diego State University (Sdsu) Foundation Methods and systems for continuous measurement of anomalies for dysmorphology analysis
US20230364187A1 (en) * 2020-09-29 2023-11-16 Cefo Co., Ltd. Composition including plgf for prevention or treatment of neuropsychologic disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849077A (en) 1984-08-06 1989-07-18 Akademie Der Wissenschaften Der Ddr Process for solid phase-sequencing of nucleic acid fragments
US7049311B1 (en) 1998-08-27 2006-05-23 Spirogen Limited Pyrrolbenzodiazepines
NO986133D0 (no) 1998-12-23 1998-12-23 Preben Lexow FremgangsmÕte for DNA-sekvensering
US6933277B2 (en) * 1999-03-12 2005-08-23 The United States Of America As Represented By The Department Of Health And Human Services Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides
US20060275782A1 (en) 1999-04-20 2006-12-07 Illumina, Inc. Detection of nucleic acid reactions on bead arrays
EP1565569A2 (fr) 2002-02-09 2005-08-24 Nanotype GmbH Procede de detection de mutations
EP1723152B1 (fr) 2004-03-09 2015-02-11 Spirogen Sàrl Pyrrolobenzodiazépines
DE102004029325A1 (de) * 2004-06-10 2006-01-05 Universität Leipzig Arzneitmittel zur Behandlung des fetalen Alkoholsyndroms
DE102004038640A1 (de) 2004-08-09 2006-02-23 Linde Kältetechnik GmbH & Co. KG Kältekreislauf und Verfahen zum Betreiben eines Kältekreislaufes
EP2230316A1 (fr) 2005-02-01 2010-09-22 AB Advanced Genetic Analysis Corporation Sequencage nucléotidique comprenant des cycles sucessifs de fromation duplex
CN101501065A (zh) * 2005-10-06 2009-08-05 特罗弗根公司 Vegf类似物及使用方法
WO2007111924A2 (fr) 2006-03-23 2007-10-04 The Board Of Trustees Of The Leland Stanford Junior University Séquençage moléculaire résolu par le déplacement d'une enzyme
CN102224422A (zh) * 2008-11-20 2011-10-19 珀金埃尔默健康科学公司 使用pigf-2和pigf-3标志物确定先兆子痫风险的方法
RU2673074C2 (ru) * 2011-12-15 2018-11-22 Майкартис Н.В. Биомаркеры и параметры для определения гипертензивных расстройств при беременности

Also Published As

Publication number Publication date
BR112019011141A2 (pt) 2019-10-01
US20190351018A1 (en) 2019-11-21
CN110225761A (zh) 2019-09-10
FR3059550A1 (fr) 2018-06-08
WO2018100143A1 (fr) 2018-06-07
AU2017367175A1 (en) 2019-06-20
CA3045080A1 (fr) 2018-06-07
KR20190109398A (ko) 2019-09-25
EP3548060A1 (fr) 2019-10-09
JP2020503275A (ja) 2020-01-30

Similar Documents

Publication Publication Date Title
CR20210201A (es) Nuevos compuestos antihelmínticos
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
JOP20180025B1 (ar) مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
BR112018001303A2 (pt) ?compostos?
MA43113B1 (fr) Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
CN110114083A (zh) 一种预防和治疗脂肪肝的方法
MA40769B1 (fr) Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MX2020011873A (es) Nuevos derivados de quinolina.
FR3059550B1 (fr) Traitement des troubles causes par l'alcoolisation foetale (tcaf)
EP4008718C0 (fr) Dérivé d'hétéroarylamidopyridinol et composition pharmaceutique le comprenant en tant que principe actif pour prévenir ou traiter une maladie auto-immune
WO2015048188A3 (fr) Facteurs de croissance des fibroblastes modifiés pour le traitement de troubles oculaires
BR112023016319A2 (pt) Anticorpos anti-beta amiloide e usos dos mesmos
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EP4029514A4 (fr) Médicament destiné au traitement curatif du syndrome d'alport rénal héréditaire réfractaire
MX2019007213A (es) Derivado de azaciclobutil triazol del grupo anular condensado, metodo de preparacion del mismo y uso del mismo en medicina.
MX2020012609A (es) Inhibidor del hif-1?, metodo de preparacion del mismo, y composicion farmaceutica para prevenir o tratar la enfermedad ocular asociada a la angiogenesis, que contiene el mismo como ingrediente activo.
EP4329753A4 (fr) Compositions pharmaceutiques et systèmes d'administration intravitréenne de médicament pour le traitement de maladies oculaires
EA202090666A1 (ru) Применение содержащей бензоат композиции для лечения глициновой энцефалопатии
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EP4364810A3 (fr) Formulations topiques et leurs utilisations
MA39406A1 (fr) Promédicament de la 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline
BR112018008835A8 (pt) composição farmacêutica oral, composição farmacêutica de liberação pulsátil oral, método para tratar uma condição de doença que requer terapia com fumarato de dimetila e método para tratar esclerose múltipla
RU2017129068A (ru) Способ лечения или профилактики атеротромботических явлений у пациентов с инфарктом миокарда в анамнезе
EP3795170C0 (fr) Composition pharmaceutique comprenant du ccn5 utilisé comme ingrédient efficace pour la prévention ou le traitement d'une maladie rétinienne

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Search report ready

Effective date: 20180608

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

ST Notification of lapse

Effective date: 20210806